

# Lucas Moreno

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2733852/publications.pdf>

Version: 2024-02-01

99  
papers

2,094  
citations

201674

27  
h-index

276875

41  
g-index

103  
all docs

103  
docs citations

103  
times ranked

3799  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 infection in children and adolescents with cancer in Madrid. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28397.	1.5	99
2	How can attrition rates be reduced in cancer drug discovery?. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 363-368.	5.0	97
3	Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. <i>European Journal of Cancer</i> , 2010, 46, 2253-2259.	2.8	86
4	High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. <i>Journal of Neuro-Oncology</i> , 2005, 71, 33-38.	2.9	80
5	Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. <i>European Journal of Cancer</i> , 2015, 51, 218-224.	2.8	80
6	Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. <i>Child's Nervous System</i> , 2010, 26, 905-911.	1.1	69
7	Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature. <i>Journal of Neuro-Oncology</i> , 2016, 126, 81-90.	2.9	68
8	Ependymoma: An Update. <i>Journal of Child Neurology</i> , 2009, 24, 1431-1438.	1.4	66
9	Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. <i>British Journal of Cancer</i> , 2016, 115, 1048-1057.	6.4	62
10	Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. <i>Cancer Letters</i> , 2016, 371, 161-170.	7.2	61
11	Early phase clinical trials of anticancer agents in children and adolescents – an ITCC perspective. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 497-507.	27.6	61
12	Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials. <i>Pediatric Blood and Cancer</i> , 2017, 64, 25-31.	1.5	61
13	Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL/SIOPEN study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27363.	1.5	53
14	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. <i>European Journal of Cancer</i> , 2019, 121, 224-235.	2.8	44
15	A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study. <i>Clinical Cancer Research</i> , 2015, 21, 267-273.	7.0	43
16	The challenge of defining ‘ultra-high-risk’ neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27556.	1.5	43
17	Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update. <i>Cancer Medicine</i> , 2017, 6, 2606-2624.	2.8	42
18	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. <i>European Journal of Cancer</i> , 2020, 136, 52-68.	2.8	42

#	ARTICLE	IF	CITATIONS
19	Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. <i>Neuro-Oncology</i> , 2013, 15, 1236-1243.	1.2	41
20	MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. <i>Current Drug Targets</i> , 2014, 15, 114-123.	2.1	40
21	Repeatability of derived parameters from histograms following non-Gaussian diffusion modelling of diffusion-weighted imaging in a paediatric oncological cohort. <i>European Radiology</i> , 2017, 27, 345-353.	4.5	40
22	Long-term follow-up of children with high-risk neuroblastoma: The ENSG5 trial experience. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1135-1140.	1.5	37
23	Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2021, 22, 1764-1776.	10.7	37
24	Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28557.	1.5	31
25	Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. <i>Journal of Neuro-Oncology</i> , 2011, 105, 135-147.	2.9	30
26	Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 109-121.	2.9	30
27	Solid ovarian tumours in childhood: a 35-year review in a single institution. <i>Clinical and Translational Oncology</i> , 2010, 12, 287-291.	2.4	29
28	A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28794.	1.5	29
29	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-11.	5.0	28
30	Toxicity and Outcome of Children and Adolescents Participating in Phase I/II Trials of Novel Anticancer Drugs. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, 218-223.	0.6	25
31	Opportunities and Challenges in Drug Development for Pediatric Cancers. <i>Cancer Discovery</i> , 2021, 11, 545-559.	9.4	25
32	miRNA-7 and miRNA-324-5p regulate alpha9-Integrin expression and exert anti-oncogenic effects in rhabdomyosarcoma. <i>Cancer Letters</i> , 2020, 477, 49-59.	7.2	24
33	Access to Clinical Trials for Adolescents and Young Adults With Cancer: A Meta-Research Analysis. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz057.	2.9	23
34	Phase I study of ceritinib in pediatric patients (Pts) with malignancies harboring a genetic alteration in ALK (ALK+): Safety, pharmacokinetic (PK), and efficacy results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10005-10005.	1.6	23
35	Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study. <i>European Radiology</i> , 2015, 25, 2641-2650.	4.5	22
36	Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. <i>European Journal of Cancer</i> , 2018, 100, 27-34.	2.8	22

#	ARTICLE	IF	CITATIONS
37	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. <i>Neuro-Oncology</i> , 2021, 23, 1597-1611.	1.2	22
38	Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma. <i>Journal of Neuro-Oncology</i> , 2013, 111, 169-176.	2.9	18
39	Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. <i>Molecular Oncology</i> , 2016, 10, 538-552.	4.6	18
40	Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics. <i>Clinical and Translational Oncology</i> , 2016, 18, 981-987.	2.4	18
41	Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study. <i>European Journal of Cancer</i> , 2016, 67, 130-140.	2.8	17
42	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. <i>Oncotarget</i> , 2017, 8, 112036-112050.	1.8	16
43	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. <i>European Journal of Cancer</i> , 2020, 141, 82-91.	2.8	15
44	Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma. <i>Cancer Research</i> , 2020, 80, 3424-3435.	0.9	15
45	Retained intravascular fragments after removal of indwelling central venous catheters: a single institution experience. <i>Journal of Pediatric Surgery</i> , 2010, 45, 1491-1495.	1.6	14
46	At the frontier of progress for paediatric oncology: the neuroblastoma paradigm. <i>British Medical Bulletin</i> , 2013, 108, 173-188.	6.9	13
47	MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. <i>Cancer Research</i> , 2019, 79, 2978-2991.	0.9	13
48	Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. <i>European Journal of Cancer</i> , 2020, 135, 89-97.	2.8	13
49	Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, e150-e153.	0.6	12
50	Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives. <i>European Journal of Cancer</i> , 2019, 114, 36-46.	2.8	12
51	Dickkopf Proteins and Their Role in Cancer: A Family of Wnt Antagonists with a Dual Role. <i>Pharmaceuticals</i> , 2021, 14, 810.	3.8	11
52	Utility of Cerebrospinal Fluid Cytology in Newly Diagnosed Childhood Ependymoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, 515-518.	0.6	10
53	Clinical research tools in pediatric oncology: challenges and opportunities. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 149-160.	5.9	9
54	Preclinical drug development for childhood cancer. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 49-64.	5.0	8

#	ARTICLE	IF	CITATIONS
55	Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care. <i>Journal of Neuro-Oncology</i> , 2018, 137, 205-213.	2.9	8
56	The First Step to Integrating Adapted Common Terminology Criteria for Adverse Events for Children. <i>Journal of Clinical Oncology</i> , 2016, 34, 2196-2197.	1.6	7
57	The development of targeted new agents to improve the outcome for children with leukemia. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 1111-1122.	5.0	7
58	Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27565.	1.5	7
59	CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models. <i>Cancers</i> , 2020, 12, 1922.	3.7	7
60	Response Assessment in Paediatric Phase I Trials According to RECIST Guidelines: Survival Outcomes, Patterns of Progression and Relevance of Changes in Tumour Measurements. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1400-1406.	1.5	6
61	A randomised phase IIb trial of BEvACizumab added to Temozolomide ± Irinotecan for children with refractory/relapsed Neuroblastoma - BEACON-Neuroblastoma, a European Innovative Therapies for Children with Cancer (ITCC) - International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS10082-TPS10082.	1.6	6
62	Abdominal Pain as the First Manifestation of Primary Pancreatic Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 222-223.	0.6	5
63	Is there a role for high dose chemotherapy with hematopoietic stem cell rescue in patients with relapsed supratentorial PNET?. <i>Journal of Neuro-Oncology</i> , 2012, 106, 441-447.	2.9	5
64	ALK-targeted therapy for poor-prognosis childhood cancers. <i>Lancet Oncology</i> , The, 2013, 14, 439-440.	10.7	5
65	High-dose etoposide and cyclophosphamide in adults and children with primary refractory and multiply relapsed acute leukaemias: The Royal Marsden experience. <i>Leukemia Research</i> , 2019, 85, 106217.	0.8	5
66	Methodological advances in the discovery of novel neuroblastoma therapeutics. <i>Expert Opinion on Drug Discovery</i> , 2021, , 1-13.	5.0	5
67	Dyspnea as the first manifestation of primary pancreatic lymphoma. <i>Pediatric Blood and Cancer</i> , 2008, 50, 434-434.	1.5	4
68	Outcome of teenagers and young adults with ependymoma: The Royal Marsden experience. <i>Child's Nervous System</i> , 2009, 25, 1047-1052.	1.1	4
69	Institutional Experience With Clofarabine and Cytarabine in Relapsed Pediatric Acute Myeloid Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, e17-e21.	0.6	4
70	Landscape of early clinical trials for childhood and adolescence cancer in Spain. <i>Clinical and Translational Oncology</i> , 2016, 18, 708-713.	2.4	4
71	Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium. <i>European Journal of Cancer</i> , 2017, 86, 275-284.	2.8	4
72	Improving the quality of care in the molecular era for children and adolescents with medulloblastoma. <i>Clinical and Translational Oncology</i> , 2019, 21, 1687-1698.	2.4	4

#	ARTICLE	IF	CITATIONS
73	Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): Dose-finding and pharmacokinetics (PK).. Journal of Clinical Oncology, 2016, 34, 10551-10551.	1.6	4
74	Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed or refractory high-risk neuroblastoma (RR-HRNB): First survival results of the ITCC-SIOPEN BEACON-Neuroblastoma phase II trial.. Journal of Clinical Oncology, 2020, 38, 10501-10501.	1.6	4
75	Diagnosis of paediatric anaplastic large-cell lymphoma: a historical perspective from a single institution. Clinical and Translational Oncology, 2009, 11, 318-321.	2.4	3
76	Targeted approaches to childhood cancer: progress in drug discovery and development. Expert Opinion on Drug Discovery, 2015, 10, 483-495.	5.0	3
77	The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clinical and Translational Oncology, 2021, 23, 2489-2496.	2.4	3
78	Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACON-Neuroblastoma randomized phase 2 trial”A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.. Journal of Clinical Oncology, 2019, 37, 10001-10001.	1.6	3
79	Old drugs still work! Oral etoposide in a relapsed medulloblastoma. Child's Nervous System, 2019, 35, 865-869.	1.1	3
80	About the Benefits of Immunotherapy for High-Risk Neuroblastoma. Journal of Clinical Oncology, 2013, 31, 649-650.	1.6	2
81	Feasibility and applicability of diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging in routine assessments of children with high-grade gliomas. Pediatric Blood and Cancer, 2017, 64, 279-283.	1.5	2
82	An active drug for TRK-positive paediatric solid tumours. Lancet Oncology, The, 2018, 19, 594-595.	10.7	2
83	Outcome of children and adolescents with central nervous system tumors in phase I trials. Journal of Neuro-Oncology, 2018, 137, 83-92.	2.9	2
84	Tumor predisposition syndromes: The challenge of de novo mutations. Pediatric Blood and Cancer, 2018, 65, e26882.	1.5	2
85	ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain. Clinical and Translational Oncology, 2019, 21, 1763-1770.	2.4	2
86	Dickkopf-1 Inhibition Reactivates Wnt/ $\beta$ 2-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo. International Journal of Molecular Sciences, 2021, 22, 12921.	4.1	2
87	Can etoposide infusion during stem cell transplantation produce a febrile reaction mimicking bacterial sepsis?. Bone Marrow Transplantation, 2008, 42, 59-60.	2.4	1
88	EPT-07PARTICIPATION OF CHILDREN AND ADOLESCENTS WITH CENTRAL NERVOUS SYSTEM TUMOURS IN PHASE I TRIALS WITHIN THE ITCC EUROPEAN CONSORTIUM. Neuro-Oncology, 2016, 18, iii25.2-iii25.	1.2	1
89	Liposomal cytarabine for the treatment of leptomeningeal dissemination of central nervous system tumours in children and adolescents. Anales De PediatrAa (English Edition), 2016, 85, 274.e1-274.e8.	0.2	1
90	Analysis of prognostic factors of clinical outcome in children and adolescents enrolled in phase I trials: a multicentre European collaborative study.. Journal of Clinical Oncology, 2015, 33, 10049-10049.	1.6	1

#	ARTICLE	IF	CITATIONS
91	How to address challenges and opportunities in pediatric cancer drug development?. Expert Opinion on Drug Discovery, 2020, 15, 869-872.	5.0	1
92	Access to early-phase clinical trials for children with relapsed and refractory neuroblastoma: A multicentre international study. Pediatric Blood and Cancer, 2022, 69, e29551.	1.5	1
93	Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clinical and Translational Oncology, 2022, , 1.	2.4	1
94	Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma: A BEACON-Neuroblastoma biomarker study.. Journal of Clinical Oncology, 2022, 40, 10039-10039.	1.6	1
95	Evaluation of chimerism by quantitative PCR analysis of DNA polymorphism after allogeneic hematopoietic stem cell transplantation in a pediatric population with malignancies. Pediatric Transplantation, 2011, 15, 81-87.	1.0	0
96	Children's clinical cancer trials: what needs to change to allow children access to new cancer drugs?. Expert Review of Clinical Pharmacology, 2015, 8, 665-667.	3.1	0
97	Early clinical trials in paediatric oncology in Spain: A nationwide perspective. Anales De Pediatr�a (English Edition), 2017, 87, 155-163.	0.2	0
98	Glioblastoma, 47XXY/45,X mosaicism, and hyperpigmented skin lesions. Pediatric Blood and Cancer, 2018, 65, e27299.	1.5	0
99	Neuronal Differentiation-Related Epigenetic Regulator ZRF1 Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro. Cancers, 2021, 13, 4845.	3.7	0